Cellectis (CLLS) Set to Post Quarterly Earnings on Thursday

Cellectis (NASDAQ:CLLS) is projected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Cellectis to announce earnings of ($0.18) per share and revenue of $15.61 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:00 AM ET.

Cellectis Trading Down 0.9%

Shares of Cellectis stock opened at $1.11 on Wednesday. Cellectis has a 12-month low of $0.88 and a 12-month high of $5.45. The company has a market cap of $111.38 million, a price-to-earnings ratio of -1.71 and a beta of 3.21. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The company’s 50-day moving average price is $1.57 and its 200-day moving average price is $2.97.

Analyst Upgrades and Downgrades

CLLS has been the topic of a number of research analyst reports. Citizens Jmp lowered shares of Cellectis from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 15th. Barclays lowered Cellectis from an “overweight” rating to an “underweight” rating and dropped their price target for the stock from $9.00 to $1.30 in a research note on Wednesday, September 16th. Robert W. Baird reduced their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 15th. Weiss Ratings upgraded shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. Finally, Wells Fargo & Company lowered their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.46.

Cellectis Company Profile

Cellectis S.A. is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments. The company’s primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.